Ireland's Perrigo Q2 profit beats on portfolio streamlining
PRGO•Outlook reaffirmed
Perrigo reaffirmed 2026 adjusted EPS guidance of $2.00 to $2.30 All In, and $2.25 to $2.55 Core.
The company expects 2026 Core organic net sales growth of (3.5)% to +0.5% and anticipates sequentially stronger second-half 2026 performance driven by cost savings and growth initiatives.
Drivers of the quarter
Perrigo said ongoing softness in consumption and lower retail inventory levels weighed on net sales and margins.
Interim CEO Albert Manzone said innovation and commercial execution drove market share gains across key categories.
Completion of the Dermacosmetics divestiture contributed to reported EPS and reduced debt.
Q2 results beat expectations
Ireland consumer self-care firm Perrigo said second-quarter revenue slightly beat analyst expectations, while adjusted earnings per share also beat consensus despite a year-over-year decline.
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Sales | Slight Beat* | $1.02 bln | $1.01 bln (3 Analysts) |
| Q2 Adjusted EPS | Beat | $0.50 | $0.34 (3 Analysts) |
| Q2 EPS | $0.63 | ||
| Q2 Adjusted Gross Margin | 35.60% |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
